International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost JTH, vol.4, p.16420554, 2006. ,
Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway, Arthritis Rheum, vol.54, p.16385547, 2006. ,
Tissue factor in the antiphospholipid syndrome, Lupus, vol.17, p.18827061, 2008. ,
IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome, Clin Exp Rheumatol, vol.10, p.1458705, 1992. ,
Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin, Circ Res, vol.88, p.11157679, 2001. ,
Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis, Arthritis Rheum, vol.43, pp.55-64, 2000. ,
Role of toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome, Arthritis Rheumatol, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02296566
Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome, JAMA J Am Med Assoc, vol.302, pp.1210-1217, 2009. ,
Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome, Int J Clin Pract, vol.58, p.15605661, 2004. ,
Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome, Neurobiol Dis, vol.30, p.18308578, 2008. ,
Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: role of reduced oxidative stress, Vascul Pharmacol, vol.71, p.25869505, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02296630
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients, J Thromb Haemost JTH, vol.11, p.23902281, 2013. ,
Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies, Thromb Haemost, vol.87, p.11916085, 2002. ,
Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug, Blood, vol.115, pp.2292-2299, 2010. ,
The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies, Rheumatol Oxf Engl, vol.57, pp.120-124, 2018. ,
Development of a thrombin generation test in cultured endothelial cells: Evaluation of the prothrombotic effects of antiphospholipid antibodies, Thromb Res, vol.169, p.30031291, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02296609
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via ?2GPI and apoER2, J Clin Invest, vol.121, p.21123944, 2011. ,
Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s, Arterioscler Thromb Vasc Biol, vol.16, p.8911269, 1996. ,
Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression, Arthritis Rheum, vol.40, pp.834-841, 1997. ,
Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome, Thromb Haemost, vol.82, p.10613637, 1999. ,
Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies, J Immunol Baltim Md, vol.153, pp.1328-1332, 1950. ,
The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome, Thromb Haemost, vol.79, p.9493575, 1998. ,
Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes, Arthritis Rheum, vol.41, pp.1420-1427, 1998. ,
Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep, Blood, vol.104, pp.2353-2358, 2004. ,
Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo, Circulation, vol.99, p.10209004, 1999. ,
Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome, Thromb Haemost, vol.109, p.23328933, 2013. ,
Thrombin generation, a function test of the haemostaticthrombotic system, Thromb Haemost, vol.96, p.17080210, 2006. ,
Thrombin generation testing in routine clinical practice: are we there yet?, Br J Haematol, vol.142, p.18564356, 2008. ,
Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity, J Thromb Haemost JTH, vol.9, p.21255251, 2011. ,
Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants, Thromb Haemost, vol.89, p.12574797, 2003. ,
Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome, Thromb Res, vol.135, p.25895847, 2015. ,
Prothrombotic Effect of Anti-beta-2 Glycoprotein-1 Antibodies on the Expression of Tissue Factor, Thrombomodulin, and Plasminogen Activator Inhibitor-1 in Endothelial Cells, Acta Medica Indones, vol.47, pp.31-37, 2015. ,
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice, Circulation, vol.96, p.9416907, 1997. ,
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial, Lancet Haematol, vol.3, p.27570089, 2016. ,
Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium, Blood, vol.131, p.29500169, 2018. ,
Attenuation of antimalarial agent hydroxychloroquine on TNF-?-induced endothelial inflammation, Int Immunopharmacol, vol.63, p.30121047, 2018. ,
Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase, Ann Rheum Dis, vol.76, p.27903507, 2017. ,
Antiphospholipid antibodyinduced cellular responses depend on epitope specificity: implications for treatment of antiphospholipid syndrome, J Thromb Haemost, vol.15, p.29024318 ,